Results 221 to 230 of about 906,600 (363)

Genetically Engineered IL12/CSF1R‐Macrophage Membrane‐Liposome Hybrid Nanovesicles for NIR‐II Fluorescence Imaging‐Guided and Membrane‐Targeted Mild Photothermal‐Immunotherapy of Glioblastoma

Advanced Science, EarlyView.
A theranostic nanoplatform is formulated with NIR‐II emissive lipophilic cyanine dye IRC18 to intercalate into genetically engineered IL12/CSF1R‐macrophage membrane‐liposome hybrid nanovesicles, which assists to achieve blood–brain barrier crossing, glioblastoma targeting, NIR‐II fluorescence imaging, image‐guided membrane‐targeted mild photothermal ...
Pengfei Chen, Yue Liu, Haiyan Huang, Menglong Li, Hui Xie, Shubham Roy, Jingsi Gu, Jian Jin, Kai Deng, Lixin Du, Bing Guo   +10 more
wiley   +1 more source

CD56 on intratumoral NK cells: orchestrating NK cell-mediated anti-tumor effects in bladder cancer. [PDF]

Neoplasia
Hassouneh Z, Noel ODV, Ji N, Kim ME, Bowman N, Svatek RS, Mace E, Mukherjee N.   +7 more
europepmc   +1 more source

Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506 [PDF]

, 1991
Abu-Elmagd, K, Alessiani, M, Bryant, J, Fung, J, Herberman, RB, Jain, A, Starzl, TE, Whiteside, TL, Wilson, J, Zeevi, A   +9 more
core  

Immunologic abnormalities in chronic fatigue syndrome

Journal of Clinical Microbiology, 1990
Nancy G. KLIMASl, Fernando R. Salvato, R. Morgan, M. Fletcher   +3 more
semanticscholar   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source

Immune-molecular interactions in high-grade serous ovarian cancer distinguish long-term survivors. [PDF]

J Clin Invest
Boudreau JE.
europepmc   +1 more source

Successful liver transplantation from crossmatch-positive donors. [PDF]

, 1981
Iwaki, Y, Iwatsuki, S, Kano, T, Klintmalm, G, Koep, LJ, Starzl, TE, Weil, R   +6 more
core  

Nanoparticle‐Mediated CXCL12–CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma

Advanced Science, EarlyView.
Molecular mechanism study of self‐assembled M2pep‐Cs NPs/Plerixafor nanoparticles in targeting MΦ reprogramming by regulating the CXCL12–CXCR4 signaling pathway to enhance immune recognition and clearance of GC (Created by BioRender). Abstract Gastric carcinoma (GC) remains a major global health challenge, requiring novel therapeutic approaches.
Qianqian Cao, Xiaolei Cheng, Rongbin Lv, Dianshui Sun, Jihua Wang, Runjia Fu, Rumei Gong, Yueying Xiao, Qin Liu, Xiaomei Li   +9 more
wiley   +1 more source

Highly sensitive live-cell imaging-based cytotoxicity assay enables functional validation of rare epitope-specific CTLs. [PDF]

Front Immunol
Wellach K, Riemer AB.
europepmc   +1 more source

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

Advanced Science, EarlyView.
Microsatellite‐stable (MSS) colorectal cancer (CRC) resists immunotherapy. PRMT5 inhibition enhances CPT‐11 sensitivity, inducing a PMS2‐deficient‐like state and cytosolic dsDNA release, which activates the cGAS‐STING pathway to promote anti‐tumor immunity. However, this combination therapy upregulates TIGIT expression on CD8+ T cells, and the addition
Jiang Zhu, Shenao Fu, Xi Zou, Hanjiang Zeng, Guangzu Cui, Yinghui Peng, Diya Tang, Fan Zhang, Hong Shen, Shan Zeng, Ying Han   +10 more
wiley   +1 more source